Alchem Laboratories is a contract research organization that focuses on process development and manufacturing of fine organic chemicals and drug substances. Dr. Emil Pop founded Alchem Laboratories in 1997 after more than three decades of technical leadership and management positions in the pharmaceutical industry. The company began operation at its current site in 1998 and has successfully concluded numerous projects for leading pharmaceutical companies and government agencies.
13305 Rachael Boulevard
Alachua, FL, 32615
James D. Talton, Ph.D., is Alchem's President and Chief Executive Officer. Prior to joining Alchem, Dr. Talton served as the President and Chief Executive Officer of Nanotherapeutics, Inc for seventeen years. Dr. Talton is a co-inventor on ten U.S. patents and has authored several peer-reviewed publications and book chapters involved in drug delivery systems with a primary focus in drug analysis and controlled release formulations, pharmacokinetics, and pulmonary drug delivery. Dr. Talton received his B.S. and M.S. in Materials Science and Engineering and his Ph.D. in Pharmaceutical Sciences from the University of Florida.
Judy Talton, MS, ARNP, is the Chief Operating Officer at Alchem. Judy received her MS in Nursing in 2009 from University of Florida and is board certified in Acute Care and Family Practice. Prior to her medical career, Judy had positions in real estate, marketing, and management.
Judy Saxon is Alchem’s Chief Financial Officer. Mrs. Saxon has 30+ years of executive financial roles, providing management leadership to private companies and investment partnership groups, while specializing in funding and investor relations. She joined Alchem in 2001. In addition to her responsibilities at Alchem as its Chief Financial Officer, Mrs. Saxon provides executive guidance to Alchem’s management team and customers. Since 2001, her expertise has contributed towards the development and financial growth of Alchem’s organization. Mrs. Saxon earned her B.S. in Business Administration from the University of Florida, with majors in accounting and finance.
Otto Geoffroy, Ph.D. is Alchem's Director of Research. He is responsible for most laboratory-scale synthetic projects. He received his Ph.D. in organic chemistry from Tulane University in 1992. Following this he was an NIH post-doctoral fellow in the Department of Pharmaceutical Sciences at the Medical University of South Carolina (1992-1994) and a post-doctoral fellow at the Hollings Cancer Center (1995-2000). Dr. Geoffroy joined Alchem in 2001 as a Senior Scientist and Group Leader. He was promoted to Director of Research in 2009.
Sergiy Denysenko, Ph.D. is Alchem's Director of Development. He oversees the scale-up laboratory and GMP manufacturing. Sergiy joined Alchem in 2001 as a Senior Research Scientist and was promoted to Principal Research Scientist in 2004 before becoming Director of Development in 2009. He received his Ph.D. in synthetic organic chemistry from Moscow State University in 1985. Following this he was Associate Professor at the Ukrainian State University of Chemical Technology (1985-1996) and a Postdoctoral Fellow and Senior Group Leader with Professor Alan Katritzky's research group at the University of Florida (1996-2001).
Vladimir Rudchenko, Ph.D. is Alchem's Technical Director. His extensive background spans more than three decades in research and industry. Dr. Rudchenko joined Alchem in 2001 and provides technical direction to both the Research and the Development groups. His academic credentials include D.Sc. in organic chemistry (Institute of Organic Chemistry, Academy of Sciences of the USSR, Moscow, 1986), Ph.D. in synthetic organic chemistry (Institute of Organic Chemistry, Academy of Sciences of the USSR, Moscow, 1977), and B.Sc. (with Distinction) in chemical engineering (Institute of Chemical Technology, Dnepropetrovsk, Ukraine, 1973). Dr. Rudchenko is an author of 13 patents and over 70 publications.
Jing Yang, Ph.D. is Alchem's Director of Quality Control. She received her undergraduate training in analytical chemistry at Shanghai University and a Ph.D in organometallic chemistry from the University of Florida. Joining Alchem in 1999 Dr. Yang was first responsible for API synthesis and process development and was promoted in 2001 to Group Leader for process development and GMP manufacturing of late-stage-experimental products. She was appointed to her current position in 2006.
Charles Alligood, A.S. is Alchem's Facilities Manager. After serving four years in the United States Coast Guard, Mr. Alligood has overseen pharmaceutical R&D facilities since 1987 and has an extensive background in instrument maintenance and hazardous waste management.